Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Should l Buy ?
Source: Globenewswire
Alpha Tau Medical Announcement: Alpha Tau Medical Ltd. has had an abstract accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium regarding their alpha-radiation cancer therapy, Alpha DaRT, specifically focusing on its application in pancreatic adenocarcinoma.
Upcoming R&D Update Day: The company will host an R&D Update Day on January 27, 2025, to discuss new data from clinical trials, including findings related to safety and efficacy of Alpha DaRT, as well as its potential use in combination therapies for various cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
